Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: Efficacy, safety, and clinical benefit assessment

Urology

Volumn 65, Issue 1, 2005, Pages 126-130

  Efstathiou, E ^a   Bozas, G ^a   Kostakopoulos, A ^a   Kastritis, E ^a   Deliveliotis, C ^a   Antoniou, N ^a   Skarlos, D ^b   Papadimitriou, C ^a   Dimopoulos, M A ^a   Bamias, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Henry Dunnant Hospital   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANDROGEN; DOCETAXEL; ESTRAMUSTINE PHOSPHATE; ZOLEDRONIC ACID;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BONE METASTASIS; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; ONYCHOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; STOMATITIS; SURVIVAL; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALOPECIA; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DIPHOSPHONATES; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESTRAMUSTINE; HUMANS; IMIDAZOLES; LIFE TABLES; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEUTROPENIA; ORCHIECTOMY; PAIN; PALLIATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOTHERAPY, HIGH-ENERGY; REMISSION INDUCTION; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 19944433918     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urology.2004.08.041     Document Type: Article

References (29)

1. M. Landstrom, J.E. Damber, A. Bergh Prostatic tumor regrowth after initially successful castration therapy may be related to a decreased apoptotic cell death rate Cancer Res 54 1994 4281 4284
2. P.R. Carroll, P.W. Kantoff, S.P. Balk Overview consensus statement newer approaches to androgen deprivation therapy in prostate cancer Urology 60 2002 1 6
3. G.W. Chodak, T. Keane, L. Klotz Critical evaluation of hormonal therapy for carcinoma of the prostate Urology 60 2002 201 208
4. W.K. Kelly, H.I. Scher, M. Mazumbar Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer J Clin Oncol 11 1993 607 615
5. E.J. Small, A. Baron, L. Fippin Ketoconazole retains activity in hormone refractory prostate cancer J Urol 157 1997 1204 1207
6. J. Picus, M. Schultz Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer preliminary results Semin Oncol 26 1999 14 18
7. W.K. Oh, P.W. Kantoff Management of hormone refractory prostate cancer current standards and future prospects J Urol 160 1998 1220 1229
8. C.A. Stein Mechanisms of action of taxanes in prostate cancer Semin Oncol 26 1999 3 7
9. J.F. Diaz, J.M. Andreu Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere reversibility, ligand stoichiometry and competition Biochem 32 1993 2747 2755
10. K.J. Pienta Preclinical mechanisms and action of docetaxel and docetaxel combinations in prostate cancer Semin Oncol 28 2001 3 7
11. M.A. Khan, M.A. Carducci, A.W. Partin The evolving role of docetaxel in the management of androgen independent prostate cancer J Urol 170 2003 1709 1716
12. D. Friedland, J. Cohen, R. Miller Jr A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer correlation of antitumor effect to phosphorylation of Bcl-2 Semin Oncol 26 1999 19 23
13. W. Berry, S. Dakhil, M.A. Gregurich Phase II trial of single agent weekly docetaxel in hormone refractory symptomatic metastatic carcinoma of the prostate Semin Oncol 28 2001 8 15
14. T.M. Beer, W.C. Pierce, B.A. Lowe Phase II study of weekly docetaxel in symptomatic androgen independent prostate cancer Ann Oncol 12 2001 1273 1279
15. C.J. Logothetis Docetaxel in the integrated management of prostate cancer current applications and future promise Oncology 16 2002 63 72
16. M. Sitka Copur, P. Ledakis, J. Lynch Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer Semin Oncol 28 2001 16 21
17. D.M. Savarese, S. Halabi, V. Hars Cancer and Leukemia Group B Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer a final report of CALGB 9780 J Clin Oncol 19 2001 2509 2516
18. V.J. Sinibaldi, M.A. Carducci, S. Moore-Cooper Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma Cancer 94 2002 1457 1465
19. D.P. Petrylak, R. MacArthur, J. O'Connor Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer Semin Oncol 26 1999 28 33
20. M.A. Eisenberger, R. DeWit, W. Berry A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC) (abstract) Proc ASCO 22 2004 2s
21. D.P. Petrylak, C. Tangen, M. Hussain SWOG 99-16 randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone (M)/prednisone (P) in men with androgen-independent prostate cancer (AIPCA) (abstract) Proc ASCO 22 2004 2s
22. F. Saad, D.M. Gleason, R. Murray A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
23. G.J. Bubley, M.A. Carducci, W. Dahut Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer recommendations from the Prostate-Specific Antigen Working Group J Clin Oncol 17 1999 3461 3467
24. A.B. Miller, B. Hoogstraten, M. Staquet Reporting results of cancer treatment Cancer 47 1981 207 214
25. G. Gravis, F. Bladou, N. Salem Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma Cancer 98 2003 1627 1634
26. L.A. Speicher, L.R. Barone, K.D. Tew Combined antimicrotubule activity of estramustine and Taxol in human prostatic carcinoma cell lines Cancer Res 52 1992 4433 4440
27. L.A. Speicher, L.R. Barone, A.E. Chapman P-glycoprotein binding and modulation of the multidrug resistant phenotype by estramustine J Natl Cancer Inst 86 1994 688 694
28. J.I. Mayordomo, A. Milla, S. Morales Biweekly docetaxel and vinorelbine as first-line chemotherapy in metastatic breast cancer Clin Breast Cancer 5 2004 131 135
29. L.G. Estevez, P. Sanchez-Rovira, M. Domine Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy in stage II and III breast cancer patients preliminary results of a phase II and pharmacogenomic study Semin Oncol 31 2 suppl 5 2004 31 36